Pancreas Cancer Trial

RTOG 0848

A Phase II-R and A Phase III Trial Evaluating both *Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Purpose

This trial studies gemcitabine with or without erlotinib followed chemotherapy with or without radiation therapy and cepcitabine or fluorouriacil in treating patients with pancreatic cancer that was removed by surgery. 

Eligibility:

This study is looking for patients with adenocarcinoma of the pancreas that have had surgery.

Learn more about this study.

S1505

Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Purpose

This trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery.

Eligibility

Patients must have pancreatic adenocarcinoma that is resectable based on CT or MRI but have not received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer.

Learn more about this study

For more information, call (260) 425-6800 and ask to speak to a clinical research coordinator. You may also e-mail oncologyresearch@parkview.com.

Parkview Cancer Institute
11050 Parkview Circle
Fort Wayne, Indiana 46845

Search By Cancer Type

 

Need assistance?

Contact us